Safety and Efficacy of Inhaled Corticosteroids (ICS) in Children with Asthma

被引:5
|
作者
Petrisko, Maria A. [2 ]
Skoner, Jonathan D. [3 ]
Skoner, David P. [1 ,4 ]
机构
[1] Allegheny Gen Hosp, Dept Pediat, Div Allergy Asthma & Immunol, Pittsburgh, PA 15212 USA
[2] Duquesne Univ, Pittsburgh, PA 15219 USA
[3] Juniata Coll, Huntingdon, PA 16652 USA
[4] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
关键词
inhaled corticosteroids; asthma; children; bone density; bone growth; hypothalamic pituitary adrenal axis; cataract; glaucoma; safety; efficacy;
D O I
10.1080/02770900802631361
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Inhaled corticosteroids (ICS) are the guideline-preferred preventative therapy for persistent asthma of all severity levels and for all ages, including children. While these drugs are unquestionably efficacious, concerns of adverse systemic effects limit patient compliance with treatment regimens and thus the attainable benefits. Suppression of bone growth, bone density. and HPA axis function, in addition to cataract formation and elevated intraocular pressure/glaucoma, have been associated with ICS use. This review will focus on recent developments in the safety and efficacy of ICS as compared to oral CS corticosteroids and the achievement of a balance between risk and benefit in optimizing ICS therapy.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条